Comparing the current results to its competitors, Eyepoint Inc reported Revenue decrease in the 1 quarter 2026 year on year by -97.15 %, despite the revenue increase by the most of its competitors of 20.63 %, recorded in the same quarter.
June 18, 2024
EyePoint Pharmaceuticals, a leading pharmaceutical company dedicated to enhancing the lives of patients with serious retinal diseases, has announced the hosting of an exclusive Research and Development (RandD) Day. The event, scheduled for June 26, 2024, aims to provide insights into the company s ongoing research efforts and showcase advancements in their therapeutic solutions. With a focus on improving patient outcomes and addressing critical unmet needs in retinal disease treatment, EyePoint is poised to make a significant impact within the field.RandD Day: A Platform for Innovation:EyePoint s RandD Day presents a unique opportunity for industry experts, healthcare professionals, investors, and the medica...
January 10, 2024
Innovative Therapeutic Approaches: EyePoint Pharmaceuticals Launches Phase 2 VERONA Clinical Trial for DME Treatment with EYP-1901In the domain of ophthalmic therapeutics, EyePoint Pharmaceuticals, Inc., a prominent player committed to enhancing health outcomes for patients with serious retinal diseases, makes another gallant stride. The initial patient, in the innovative Phase 2 VERONA clinical trial of EYP-1901 for the treatment of Diabetic Macular Edema (DME), has been successfully dosed, as revealed by the company on January 10, 2024.The trial is another landmark in EyePoint’s continuous and sustained commitment to redefining therapeutics for serious retinal diseases. The development of EYP-1901 involv...
December 4, 2023
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock and Impressive Revenue Growth in Q3 2023 WATERTOWN, Mass., Dec. 04, 2023 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a leading biopharmaceutical company dedicated to developing and commercializing innovative treatments for serious retinal diseases, has made two significant announcements. Firstly, EyePoint announced that it has initiated an underwritten public offering of $175 million of its common stock. Secondly, the company reported an impressive revenue increase of 51.84% in the third quarter of 2023, exceeding the average revenue growth of its competitors. The public offering of $175 million of shares of EyePoint s c...
Tarsus Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing novel therapeutics to treat various eye diseases. Their business model involves identifying promising drug candidates, conducting rigorous research and clinical trials, and seeking regulatory approvals for their products. They then partner with larger pharmaceutical companies or directly market and sell their approved therapies to healthcare providers and patients to generate revenue.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Outlook Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing monoclonal antibody-based therapies for various ophthalmic indications. Their business model revolves around leveraging their expertise in developing cost-effective, innovative treatments that address unmet medical needs in the ophthalmic market.
Ocular Therapeutix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases and conditions of the eye. They utilize their proprietary hydrogel technology to design and manufacture sustained-release treatments that can be administered during routine eye exams and eliminate the need for patient compliance with eye drops.
Sources:
Eyepoint Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Eyepoint Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
